Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism

Table 5

Treatments administered to patients with GEP-NETs.

(a)

	Gastric, (%)	Duodenum, (%)	Rectum, (%)
Endoscopic therapy ()	21 (52.5)	4 (10.0)	15 (37.5)

(b)

	NET G1	NET G2	NEC
Surgical therapy ()^$	125 out of 155 (80.6)	48 out of 60 (80.0)	18 out of 25 (72.0)	0.607
Surgery of metastases ()^$	22 out of 121 (18.2)	9 out of 44 (20.5)	8 out of 18 (44.4)	0.055
Liver ablative therapy
TAE ()^$	7 out of 131 (5.3)	3 out of 49 (6.1)	0 out of 19 (0.0)	0.781
RFA ()^$	3 out of 61 (4.9)	1 out of 27 (3.7)	0 out of 13 (0.0)	>0.999
Systemic therapies
Somatostatin analogues ()^$	31 out of 152 (20.4)	32 out of 54 (59.3)	8 out of 25 (32.0)	<0.001
Interferon ()^$+SSAs	3 out of 152 (2.0)	1 out of 55 (1.8)	0 out of 24 (0.0)	>0.999
Target therapies ()^$	2 out of 153 (1.3)	2 out of 53 (3.8)	3 out of 25 (12.0)	0.020
PRRNT ()^$	3 out of 150 (2.0)	6 out of 55 (10.9)	0 out of 25 (0.0)	0.021
Chemotherapy ()^$	3 out of 157 (1.9)	6 out of 60 (10.0)	11 out of 27 (40.7)	<0.001

^$Number of cases with information. TAE = transhepatic arterial embolization; RFA = radiofrequency ablation; PRRNT: peptide receptor radionuclide therapy. Sunitinib; ¹⁷⁷Lu-THERA.